vs
Ingevity Corp（NGVT）とPrestige Consumer Healthcare Inc.（PBH）の財務データ比較。上の社名をクリックして会社を切り替えられます
Prestige Consumer Healthcare Inc.の直近四半期売上が大きい（$283.4M vs $185.4M、Ingevity Corpの約1.5倍）。Prestige Consumer Healthcare Inc.の純利益率が高く（16.5% vs -45.6%、差は62.1%）。Ingevity Corpの前年同期比売上増加率が高い（36.7% vs -2.4%）。Prestige Consumer Healthcare Inc.の直近四半期フリーキャッシュフローが多い（$75.3M vs $73.5M）。過去8四半期でPrestige Consumer Healthcare Inc.の売上複合成長率が高い（1.2% vs -26.2%）
インジェビティコープは世界的な特殊化学品・先端材料メーカーで、高性能炭素材料、舗装保全ソリューション、特殊化学製品を生産しています。自動車排出ガス制御、工業浄化、道路インフラ、農業資材を主要市場とし、事業は北米、欧州、アジア太平洋地域に展開しています。
プレステージ・コンシューマー・ヘルスケア社はアメリカの企業で、一般用医薬品のヘルスケア製品および家庭用洗浄製品の販売・流通を手がけています。1996年にMedtech Products社、Prestige Brands International社、Spic and Span社の合併により設立され、本社はニューヨーク州タリータウン、バージニア州リンチバーグに製造工場を構えています。
NGVT vs PBH — 直接比較
損益計算書 — Q4 FY2025 vs Q3 FY2026
| 指標 | | |
|---|---|---|
| 売上 | $185.4M | $283.4M |
| 純利益 | $-84.6M | $46.7M |
| 粗利率 | 41.2% | 55.5% |
| 営業利益率 | -47.7% | 29.1% |
| 純利益率 | -45.6% | 16.5% |
| 売上前年比 | 36.7% | -2.4% |
| 純利益前年比 | -609.6% | -23.5% |
| EPS（希薄化後） | $-2.33 | $0.97 |
緑 = その指標でリード。会計年度がずれている場合は期間が異なる場合あり
8四半期 売上・利益トレンド
並べて比較する四半期履歴。決算期がずれていても暦四半期で整列
| Q4 25 | $185.4M | $283.4M | ||
| Q3 25 | $333.1M | $274.1M | ||
| Q2 25 | $365.1M | $249.5M | ||
| Q1 25 | $284.0M | $296.5M | ||
| Q4 24 | $135.6M | $290.3M | ||
| Q3 24 | $333.8M | $283.8M | ||
| Q2 24 | $390.6M | $267.1M | ||
| Q1 24 | $340.1M | $277.0M |
| Q4 25 | $-84.6M | $46.7M | ||
| Q3 25 | $43.5M | $42.2M | ||
| Q2 25 | $-146.5M | $47.5M | ||
| Q1 25 | $20.5M | $50.1M | ||
| Q4 24 | $16.6M | $61.0M | ||
| Q3 24 | $-107.2M | $54.4M | ||
| Q2 24 | $-283.7M | $49.1M | ||
| Q1 24 | $-56.0M | $49.5M |
| Q4 25 | 41.2% | 55.5% | ||
| Q3 25 | 40.2% | 55.3% | ||
| Q2 25 | 37.8% | 56.2% | ||
| Q1 25 | 39.9% | 57.3% | ||
| Q4 24 | 81.3% | 55.5% | ||
| Q3 24 | 39.4% | 55.5% | ||
| Q2 24 | 31.5% | 54.7% | ||
| Q1 24 | 29.3% | 54.8% |
| Q4 25 | -47.7% | 29.1% | ||
| Q3 25 | 18.7% | 29.1% | ||
| Q2 25 | -39.1% | 28.8% | ||
| Q1 25 | 9.4% | 29.8% | ||
| Q4 24 | — | 31.7% | ||
| Q3 24 | 33.0% | 29.7% | ||
| Q2 24 | 25.9% | 27.0% | ||
| Q1 24 | 22.6% | 29.7% |
| Q4 25 | -45.6% | 16.5% | ||
| Q3 25 | 13.1% | 15.4% | ||
| Q2 25 | -40.1% | 19.0% | ||
| Q1 25 | 7.2% | 16.9% | ||
| Q4 24 | 12.2% | 21.0% | ||
| Q3 24 | -32.1% | 19.2% | ||
| Q2 24 | -72.6% | 18.4% | ||
| Q1 24 | -16.5% | 17.9% |
| Q4 25 | $-2.33 | $0.97 | ||
| Q3 25 | $1.18 | $0.86 | ||
| Q2 25 | $-4.02 | $0.95 | ||
| Q1 25 | $0.56 | $1.00 | ||
| Q4 24 | $0.44 | $1.22 | ||
| Q3 24 | $-2.94 | $1.09 | ||
| Q2 24 | $-7.81 | $0.98 | ||
| Q1 24 | $-1.54 | $0.98 |
貸借対照表と財務力
直近四半期の流動性・レバレッジ・純資産のスナップショット
| 指標 | | |
|---|---|---|
| 現金・短期投資手元流動性 | $78.1M | $62.4M |
| 総負債低いほど良い | $1.2B | $1.0B |
| 株主資本純資産 | $29.7M | $1.8B |
| 総資産 | $1.7B | $3.5B |
| 負債/資本比率低いほどレバレッジが低い | 39.10× | 0.56× |
8四半期トレンド — 暦四半期で整列
| Q4 25 | $78.1M | $62.4M | ||
| Q3 25 | $83.4M | $119.1M | ||
| Q2 25 | $76.9M | $139.5M | ||
| Q1 25 | $71.5M | $97.9M | ||
| Q4 24 | $68.0M | $50.9M | ||
| Q3 24 | $135.5M | $51.5M | ||
| Q2 24 | $107.4M | $34.3M | ||
| Q1 24 | $88.5M | $46.5M |
| Q4 25 | $1.2B | $1.0B | ||
| Q3 25 | $1.2B | $993.1M | ||
| Q2 25 | $1.2B | $992.7M | ||
| Q1 25 | $1.3B | $992.4M | ||
| Q4 24 | $1.3B | $992.0M | ||
| Q3 24 | $1.4B | $1.1B | ||
| Q2 24 | $1.4B | $1.1B | ||
| Q1 24 | $1.4B | $1.1B |
| Q4 25 | $29.7M | $1.8B | ||
| Q3 25 | $138.1M | $1.8B | ||
| Q2 25 | $120.7M | $1.9B | ||
| Q1 25 | $234.6M | $1.8B | ||
| Q4 24 | $195.2M | $1.8B | ||
| Q3 24 | $214.5M | $1.7B | ||
| Q2 24 | $284.8M | $1.7B | ||
| Q1 24 | $568.2M | $1.7B |
| Q4 25 | $1.7B | $3.5B | ||
| Q3 25 | $1.8B | $3.4B | ||
| Q2 25 | $1.9B | $3.4B | ||
| Q1 25 | $2.1B | $3.4B | ||
| Q4 24 | $2.0B | $3.3B | ||
| Q3 24 | $2.2B | $3.3B | ||
| Q2 24 | $2.3B | $3.3B | ||
| Q1 24 | $2.6B | $3.3B |
| Q4 25 | 39.10× | 0.56× | ||
| Q3 25 | 8.39× | 0.54× | ||
| Q2 25 | 10.24× | 0.54× | ||
| Q1 25 | 5.68× | 0.54× | ||
| Q4 24 | 6.86× | 0.55× | ||
| Q3 24 | 6.52× | 0.61× | ||
| Q2 24 | 4.92× | 0.65× | ||
| Q1 24 | 2.48× | 0.68× |
キャッシュフローと資本効率
再投資後に実際に生み出すキャッシュ。純利益より操作が難しい
| 指標 | | |
|---|---|---|
| 営業キャッシュフロー直近四半期 | $97.1M | $78.3M |
| フリーキャッシュフロー営業CF - 設備投資 | $73.5M | $75.3M |
| FCFマージンFCF / 売上 | 39.6% | 26.6% |
| 設備投資強度設備投資 / 売上 | 12.7% | 1.1% |
| キャッシュ転換率営業CF / 純利益 | — | 1.68× |
| 直近12ヶ月FCF直近4四半期 | $273.5M | $267.2M |
8四半期トレンド — 暦四半期で整列
| Q4 25 | $97.1M | $78.3M | ||
| Q3 25 | $129.7M | $57.5M | ||
| Q2 25 | $79.0M | $79.0M | ||
| Q1 25 | $25.4M | $61.8M | ||
| Q4 24 | $64.5M | $65.1M | ||
| Q3 24 | $46.5M | $69.8M | ||
| Q2 24 | $29.7M | $54.8M | ||
| Q1 24 | $-12.1M | $66.9M |
| Q4 25 | $73.5M | $75.3M | ||
| Q3 25 | $117.8M | $55.4M | ||
| Q2 25 | $66.8M | $78.2M | ||
| Q1 25 | $15.4M | $58.4M | ||
| Q4 24 | $39.6M | $63.5M | ||
| Q3 24 | $28.5M | $67.8M | ||
| Q2 24 | $11.6M | $53.6M | ||
| Q1 24 | $-28.7M | $63.8M |
| Q4 25 | 39.6% | 26.6% | ||
| Q3 25 | 35.4% | 20.2% | ||
| Q2 25 | 18.3% | 31.3% | ||
| Q1 25 | 5.4% | 19.7% | ||
| Q4 24 | 29.2% | 21.9% | ||
| Q3 24 | 8.5% | 23.9% | ||
| Q2 24 | 3.0% | 20.1% | ||
| Q1 24 | -8.4% | 23.0% |
| Q4 25 | 12.7% | 1.1% | ||
| Q3 25 | 3.6% | 0.8% | ||
| Q2 25 | 3.3% | 0.3% | ||
| Q1 25 | 3.5% | 1.2% | ||
| Q4 24 | 18.4% | 0.5% | ||
| Q3 24 | 5.4% | 0.7% | ||
| Q2 24 | 4.6% | 0.4% | ||
| Q1 24 | 4.9% | 1.1% |
| Q4 25 | — | 1.68× | ||
| Q3 25 | 2.98× | 1.36× | ||
| Q2 25 | — | 1.66× | ||
| Q1 25 | 1.24× | 1.23× | ||
| Q4 24 | 3.89× | 1.07× | ||
| Q3 24 | — | 1.28× | ||
| Q2 24 | — | 1.12× | ||
| Q1 24 | — | 1.35× |
財務フロー比較
売上 → 粗利 → 営業利益 → 純利益のサンキー図
セグメント別売上内訳
NGVT
| Performance Materials | $151.2M | 82% |
| Advanced Polymer Technologies Segment | $36.5M | 20% |
PBH
| Womens Health | $51.8M | 18% |
| International OTC Healthcare | $47.7M | 17% |
| Gastrointestinal | $44.2M | 16% |
| Eye And Ear Care | $35.2M | 12% |
| Dermatologicals | $27.6M | 10% |
| Analgesics | $26.7M | 9% |
| Oral Care | $23.5M | 8% |
| Cough And Cold | $23.0M | 8% |
| Other Otc | $3.6M | 1% |
